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Expression of chloride channel 1 (CLCN1/ClC-1) in skeletal muscle is driven by alternative splicing, a
process regulated in part by RNA-binding protein families MBNL and CELF. Aberrant splicing of CLCN1
produces many mRNAs, which were translated into inactive proteins, resulting in myotonia in myotonic
dystrophy (DM), a genetic disorder caused by the expansion of a CTG or CCTG repeat. This increase in
abnormal splicing variants containing exons 6B, 7A or the insertion of a TAG stop codon just before exon
7 leads to a decrease in expression of the normal splice pattern. The majority of studies examining
splicing in CLCN1 have been performed using mouse Clcn1, as have investigations into the activation and
suppression of normal splicing variant expression by MBNL1-3 and CELF3–6, respectively. In contrast,
examinations of human CLCN1 have been less common due to the greater complexity of splicing patterns.
Here, we constructed a minigene containing CLCN1 exons 5–7 and established a novel assay system to
quantify the expression of the normal splicing variant of CLCN1 using real-time RT-PCR. Antisense oli-
gonucleotides could promote normal CLCN1 alternative splicing but the effective sequence was different
from that of Clcn1. This result differs from previous reports using Clcn1, highlighting the effect of dif-
ferences in splicing patterns between mice and humans.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Myotonic dystrophy (dystrophia myotonica, DM) is an auto-
somal dominant disorder and the most common form of inherited
muscular dystrophy in adults [1]. DM is characterised by a wide
range of symptoms, including myotonia, progressive muscle loss,
cataracts, cardiac conduction defects, insulin resistance and cog-
nitive impairments [2]. Two forms of DM, DM1 and DM2, have
been described to date. In DM1, disease symptoms result from an
aberrant expansion of the CTG trinucleotide repeat in the 3′ un-
translated region (UTR) in myotonic dystrophy protein kinase
(DMPK) on chromosome 19 [3–5]. In DM2, disease is caused by an
expansion of a CCTG tetranucleotide repeat in intron 1 of the
CCHC-type zinc ﬁnger, nucleic acid binding protein (CNBP) gene on
chromosome 3 [6]. Among patients with DM, several lines of
evidence have suggested a relationship between transcribed RNA
CUG or CCUG repeats and disease symptoms. First, the number of
CUG repeats correlates with the severity of symptoms [5]. Second,
in cells derived from patients with DM, expanded CUG and CCUG
repeats accumulate in the nucleus [6–8]. Third, HSALR transgenicB.V. This is an open access article u
. Ishiura).
work.mice expressing an expanded CUG repeat inserted in the human
skeletal muscle actin (HSA) gene manifest myotonia and abnormal
muscle histology [9].
In addition to sequence repeats, abnormalities in RNA metabo-
lism have also been found in patients with DM. Aberrant splicing
has been reported in multiple genes, including chloride channel 1
(CLCN1), insulin receptor (INSR), bridging integrator 1 (BIN1), myo-
mesin 1 (MYOM1) and actin-binding LIM protein 1 (ABLIM1), among
others [10–14], leading to a variety of symptoms in these patients.
This aberrant splicing is thought to be driven by two families of
splicing factors, muscleblind-like (MBNL) and CUG binding protein/
ELAV-like family (CELF). MBNL proteins MBNL1–3 bind CHG/CHHG
(H: A, C and U) sequences of RNA and co-localise with mRNAs
containing CUG expanded repeats [15]. This process leads to a de-
crease in the intracellular concentrations of functionally available
MBNL proteins. Alternatively, CELF proteins, especially CELF1 and
CELF2, are activated by CUG repeats, although the pathways reg-
ulating this process have not been fully elucidated [16]. This im-
balance of MBNL and CELF in turn leads to abnormal splicing of
downstream genes, further exacerbating DM symptoms.
Here, we examine the effects of MBNL1-3 and CELF1-6 on DM.
CLCN1 is thought to be responsible for myotonia, the most char-
acteristic symptom in DM1 [17]. Many studies have been performed
using mouse Clcn1. In these models, a frameshift occurs followingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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these immature mRNA transcripts are then degraded by the non-
sense-mediated mRNA decay (NMD) machinery, resulting in lower
steady state levels of CLCN1 protein. Correction of the abnormal
splicing patterns in HSALR transgenic mice has been shown to res-
cue this phenotype, leading to recovery from myotonia [18].
Moreover, in Clcn1, MBNL1–3 decrease the insertion of exon 7A,
whereas CELF3–6 increase it [19]. However, chloride channelopathy
in DM1 has been reported to be due to downregulation of CLCN1
transcription [20]. So, the mechanism of myotonia in DM1 is
controversial.
Far less is known regarding the function of human CLCN1, as
mouse and human CLCN1 exhibit distinctly different splicing pat-
terns. CLCN1 encodes for two additional exons, 6B (55 bp) not
present in the mouse orthologue and 7A (79 bp) between exons
6 and 7; insertion of either or both of these exons into Clcn1 re-
sults in a frameshift mutation. Alternative splicing of these exons
has been shown to produce numerous variants in the skeletal
muscle of patients with DM, including variants such as 5–6B–7A–
7–8, 5–6–6B–7A–7–8 and 5–8 [17]. Beyond these two additional
exons, another splicing pattern characterised by a three base pair
(TAG triplet) extension of exon 7 has also been detected [10]. This
inserted TAG sequence is thought to act as a stop codon, resulting
in the production of the immature mRNA.
To better understand the mechanism of splicing in CLCN1, we
began by constructing a minigene spanning exons 5–7 of CLCN1,
resulting in the synthetic CLCN1 (5–7) minigene. We also estab-
lished a new assay using real-time reverse transcription (RT)-PCR,
which can distinguish between splicing variants based upon the
presence of the TAG-inserted pattern. We found signiﬁcant dif-
ferences between the human and mouse orthologue, which may
have important implications for the study of DM.2. Materials and methods
2.1. Cell culture, transfection and RNA extraction
HEK293 cells were grown in Dulbecco's modiﬁed Eagle's
medium (DMEM) containing 10% foetal bovine serum (FBS) and
subcultured at 90–100% conﬂuence. HEK293 cells were plated at
6.0105 cells on 6-well plates 24 h before transfection. For RT-
PCR analyses, the CLCN1 (5–7) minigene (1.0 mg) was transfected
with 3.0 mL FuGENE 6 (Promega). In the cellular splicing assay,
minigenes (0.2 mg) and splicing factor constructs (0.8 mg) were
transfected with 3.0 mL FuGENE 6. For antisense analysis, HEK293
cells were cultured in 12-well plates and transfected with mini-
genes (0.1 mg) and AONs (antisense oligonucleotides: phosphor-
othioate 2′ O-methyl RNA oligonucleotides (Coralville, IA) listed in
Supplementary Table ST1, 50 pmol) using 4.0 mL Lipofectamine
2000 at 50–60% conﬂuence and incubated for 48 h; total RNA was
extracted using a GenElute Mammalian Total RNA Miniprep Kit
with DNase treatment (Sigma-Aldrich), as described previously
[13,14,21].
2.2. RT-PCR and sequence analysis
For cDNA synthesis, 1.0 mg of total RNA was reverse-transcribed
with a PrimeScript 1st Strand cDNA synthesis Kit (TaKaRa Bio) in a total
volume of 10 mL using oligo(dT) primers. cDNA samples were then
diluted ﬁvefold prior to use. PCR was performed using Ex Taq DNA
polymerase (TaKaRa Bio) according to the manufacturer's protocol. For
sequence analysis of the CLCN1 (5–7) minigene, PCR was carried out
using the following primer set: forward (5′-CATGGTCCTGCTG-
GAGTTCGTG-3′) and reverse (5′-CTCCAAGTGGTGTCCCAAAACAAC-3′).
PCR conditions were as follows: an initial denaturation step at 96 °C for2min, 30 cycles at 96 °C for 30 s, 62 °C for 30 s and 72 °C for 30 s, and a
ﬁnal extension step of 72 °C for 5min. PCR products were then sepa-
rated via 8% polyacrylamide gel electrophoresis and soaked in ethidium
bromide solution (1 mg/ml); then the relevant bands were extracted
from the gel. The spliced gel was shaken in solution buffer (0.5 M
ammonium acetate and 1mM EDTA in sterilised water) for 48 h, after
which the products were washed in isopropyl alcohol followed by
ethanol precipitation. Precipitates were then dissolved in a volume of
5 mL sterilised water. The puriﬁed DNA fragment was inserted into a
pGEM-TEasy vector (Promega) using a Rapid DNA Ligation Kit (Roche)
and sequenced to conﬁrm proper insertion.
2.3. Real-time PCR
Expression of the normal splicing pattern variant of CLCN1 was
quantiﬁed using a relative standard curve method following ampliﬁ-
cation on a StepOnePlus Real-Time PCR System (Life Technologies).
Reactions were performed using the Power SYBR Green PCR Master
Mix (Life Technologies). PCR reaction was performed in a total volume
of 10 mL using cDNA samples (1 mL). PCR conditions were as follows:
an initial denaturation step at 96 °C for 20 s, followed by 40–55 cycles
at 96 °C for 30 s and 67 °C for 30 s, and a ﬁnal melt curve step at 96 °C
for 30 s, 67 °C for 30 s and 96 °C for 30 s. Expression of the normal
splicing pattern was compared against the expression of GFP in the
CLCN1 (5–7) minigene relative to the mock control. Each threshold
cycle value (Ct-value) was calculated as an average of three replicates,
with undetermined values treated as 0. Another mock sample
(pcDNA3.1) was used as the control baseline for calculating relative
quantiﬁcation (RQ) value. The normal splicing pattern was ampliﬁed
using the CLCN1 (5–6–7) primer set: forward (5′-GTTCTGCGGGGTA-
TATGAaCA-3′) and reverse (5′-CTCCAAGTGGTGTCCCAAAACAAC-3′);
GFP was ampliﬁed using the following primers: forward (5′-AAGTT-
CAGCGTGTCCGG-3′) and reverse (5′-TGTCGCCCTCGAACTTC-3′). Each
primer set was adjusted to a ﬁnal concentration of 500 nM.
2.4. Standard curve
To draw the standard curve, initial templates were diluted in
sterile water and supplemented with 0.2 pg/mL salmon sperm
single strand DNA (D1626, Sigma), followed by a series of four
ninefold dilutions. The pGEM-TEasy vector (Promega) containing
the normal splicing pattern insert was used as the control tem-
plate at a starting concentration of 1 ng/mL. GFP controls were
ampliﬁed from mock control cDNA. Variance between replicates
due to high annealing and extension temperatures was limited by
using standard curves with an R240.95.
2.5. Protein extraction
Transfected cells were harvested in sonication buffer (0.1%
Triton X-100, 0.1% protease inhibitor mix in phosphate-buffered
saline, PBS) and disrupted 10 times by sonication using Soniﬁer
450 disruptor (Branson) with an output of 3 and a duty cycle of
10%. After sonication, protein concentrations were quantiﬁed using
a DC Protein Assay (Bio-Rad) according to the manufacturer's in-
structions. Brieﬂy, each sample was diluted to 2 mg/mL with PBS
and diluted twofold in 2 sample buffer to a ﬁnal concentration
of 1 mg/mL. Samples were stored at 80 °C.
2.6. Western blotting
Samples were resolved by SDS-PAGE and transferred to PVDF
membranes (Immobilon-P, Millipore). The membranes were then
blocked with 5% skim milk in PBS with 0.05% Tween 20 (PBST) for
1 h at room temperature and then incubated overnight at 4 °C
with primary antibodies, anti-myc (1:5000, R950-25; Invitrogen)
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washing, the membranes were incubated for 1 h in horseradish
peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling
Technologies) at room temperature. The immunoreactive bands
were visualised by enhanced chemiluminescence (ECL) and scan-
ned using an LAS-3000 image analyser (FujiFilm).
2.7. Constructs
The CLCN1 (5–7) minigene was constructed using the CLCN1
minigene [19], which spans exons 6–7 of CLCN1. The genomic
fragment covering exon 5 and intron 5 was ampliﬁed by nested
PCR using PrimeSTAR GXL DNA Polymerase (TaKaRa Bio) from
human genomic DNA (Promega). The ﬁrst fragment containing
exons 5–6 was ampliﬁed using the following primer set: forward
(5′-AGAACTTGCCACCAGACTCG-3′) and reverse (5′-TGGACTAG-
CAGGGAGAGCAT-3′). The second fragment was ampliﬁed using
the ﬁrst fragment as template with the following primers: forward
(5′-AAAGATCTGGAATCCCCGAAATGAA-3′) and reverse (5′-TGGAC-
TAGCAGGGAGAGCAT-3′). The second fragment was then inserted
into the BglII–XapI site of the CLCN1 minigene and sequenced to
conﬁrm proper recombination. Splicing factors MBNL1, MBNL2,
MBNL3, CELF1, CELF2, CELF3, CELF4, CELF5 and CELF6 were cloned
as described previously into pSec-DK, a mammalian expression
vector with a myc-tag and 6 His-tag modiﬁed from pSecTagA
(Invitrogen) by deleting the Igκ chain leader sequence [19].
2.8. Mutagenesis
The ﬁrst fragment of the CLCN1 (A4T) minigene and the
second fragment of the CLCN1(ΔTAG) minigene were ampliﬁed
with PrimeSTAR GXL DNA Polymerase (TaKaRa Bio) using the
CLCN1(5–7) minigene as a template. The following primer sets
were used for PCR ampliﬁcation: ﬁrst fragment, forward
(5′-CTCTGTCTGTCTCTCCCCTtGTAGCAGCCATACTACTACTCTG-3′)
and reverse (5′-CAGAGTAGTAGTATGGCTGCTACaAGGGG-
AGAGACAGACAGAG-3′) and second fragment, forward (5′-
CCTGTTTCTCTGTCTGTCTCTCCCC_TAGCAGCCATACTACTACTCTG-
3′) and reverse (5′-CAGAGTAGTAGTATGGCTGCTA_GGGGAGA-
GACAGACAGAGAAACAGG-3′). PCR products were then treated
with DpnI and inserted into the HindIII–SalI site of the CLCN1
(5–7) minigene. Each minigene was sequenced before use to
conﬁrm proper insertion.EGFP 5 6 6
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3.1. Splicing pattern of the CLCN1 (5–7) minigene
This study was performed using the CLCN1 (5–7) minigene,
which consisted of exons 5–7 of CLCN1 inserted into a pEGFP-C1
expression vector (Fig. 1A). This vector was then transfected into
HEK293 cells and analysed by RT-PCR to compare the splicing
patterns of the human construct to that of the mouse orthologue
(Fig. 1B). Several splicing patterns were observed, including exons
5–6–6B–7A–7, 5–6B–7A–7 and 5–6–7 [17]. These patterns are in
stark contrast to that of Clcn1, which contains only exons 5–6–7
and 5–6–7A–7 (Fig. 1). As frameshifts are known to occur in all
constructs expressing exons 6B or 7A, these splicing variants are
likely to result in the production of inactive proteins or mRNAs,
which would be degraded via nonsense-mediated mRNA decay
(NMD). The normal spliced band containing exons 5–6–7 (286 bp)
and an abnormally spliced one containing exons 5–7A–7 (287 bp)
were indistinguishable by electrophoresis, limiting our ability to
quantify production of the normal splice variant.
3.2. Reappearance of the TAG-inserted pattern in the CLCN1 (5–7)
minigene
During the analysis of the CLCN1 (5–7) minigene splicing, we
detected an additional splicing variants containing a TAG sequence
just before exon 7 (Fig. 2A). We refer to this splicing pattern as the
“TAG-inserted pattern”. This splicing pattern was found in exons
5–7A–7, 5–7 and 5–6–7, suggesting that a TAG sequence can exist
in each of the bands shown in Fig. 1B. Because the TAG sequence
encodes for a stop codon, these splicing variants also produce the
mRNAs which are translated into inactive proteins. The frequency
of the TAG-inserted pattern has previously been investigated
across all splicing variants of CLCN1 [10]. Here, we performed RT-
PCR followed by sequencing of the 5–6–7 splice band from human
skeletal muscle biopsies to determine the ratio of the TAG-inserted
pattern relative to that of the 5–6–7 splicing pattern (Fig. 2B). The
observed ratio was found to be highly variable between in-
dividuals, with no signiﬁcant difference in the percentage of the
TAG inserted pattern between DM and controls.
To determine the mechanism underlying TAG insertion, we
examined the sequence immediately upstream of exon 7, revealing
two tandem TAG sequences (Fig. 2C). We hypothesised that theB 7 7A 
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Fig. 2. Analysis of the TAG-inserted pattern. (A) The structure of the TAG-inserted pattern. In this pattern, a TAG sequence that encodes for a stop codon is inserted
immediately upstream of exon 7. (B) The percentage of the TAG-inserted pattern in normal-sized splicing variants in human skeletal muscle biopsies (Non-DM1-5: 8mo(M),
2y(M), 31y(F), 34y(M), 42y(M), respectively ; DM1-5: 8mo(M), 2y(M), 11y(M), 36y(M), 41y(M), respectively). We performed RT-PCR and sequenced the band corresponding
to the normal splicing pattern 15 times for each individual. Interindividual variances in the percentage of TAG-inserted pattern transcripts were evident, but these differences
were not signiﬁcantly different between DM and control groups. (C) Sequences adjacent to exon 7. Two tandemly repeated TAG sequences were detected just before exon 7.
(D) Analysis of the acceptor site in TAG-inserted pattern transcripts. Two mutant CLCN1minigenes were constructed: CLCN1 (A4T), in which the TAG sequence was mutated
to TTG, and CLCN1ΔTAG, in which the TAG sequence was deleted. (E) Analysis of the percentage of the TAG-inserted pattern inclusion in each construct. The TAG-inserted
pattern was completely absent in each of the two mutant constructs.
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splicing. To conﬁrm this hypothesis, we generated two constructs:
one in which the upstream TAG sequence was mutated to TTG,
CLCN1 (A4T), and the other in which the upstream TAG sequence
was deleted, CLCN1ΔTAG (Fig. 2D). These constructs were then
transfected into HEK293 cells, and the resulting transcripts were
analysed by RT-PCR and sequenced. The TAG-inserted pattern was
shown to be completely lost in each construct (Fig. 2E), indicating
that the upstream TAG sequence, particularly the ‘AG’ residues,
serves as the new acceptor site to produce the TAG-inserted
pattern.
3.3. Establishment of a new assay system to quantify the normal
splicing pattern variant
Based upon the various splicing patterns observed in the ﬁrst
round of analyses, we developed a new assay to quantify the
normal splicing pattern variant by real-time RT-PCR using a primer
set speciﬁc for those sequences. In this assay, the forward primerannealed to the junction of exons 6 and 7, and the reverse primer
annealed to exon 7. Complementarity between the two bases on
the 5′ end of exon 7 was used to distinguish the 5–6–7 splicing
variant from that of the TAG-inserted pattern (Fig. 3A, left).
However, as this forward primer is also complementary to a por-
tion of the TAG-inserted pattern (Fig. 3A, right), this primer set
was able to amplify both the 5–6–7 and the TAG-inserted patterns
under standard PCR conditions. Next, we designed the forward
primer to have one mismatch in the four bases complementary to
the TAG-inserted pattern, so that the complementarity between
the primer and the TAG-inserted pattern is suppressed (Fig. 3B).
This primer set was referred to as CLCN1 (5–6–7).
Finally, we optimised our PCR conditions using the CLCN1 (5–
6–7) primer set. Generally, real-time PCR is performed in two
steps containing a single denaturation followed by an annealing
and extension step. Plasmid vectors containing the 5–6–7 and the
TAG-inserted pattern sequences were used as the template and
analysed by gradient PCR. Speciﬁc ampliﬁcation of the 5–6–7
splicing pattern was observed at temperatures 467.1 °C (Fig. 3C);
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Fig. 3. The establishment of the assay system. (A) The original primer set. Theo-
retically, the forward primer should anneal to the junction of exons 6 and 7, re-
sulting in speciﬁc ampliﬁcation of the normal splicing pattern; however, this for-
ward primer is complementary to a portion of the TAG-inserted pattern, resulting
in ampliﬁcation of this region under standard PCR conditions. (B) A schematic
diagram of the CLCN1 (5–7) forward primer. The original primer was modiﬁed to
include one mismatch in the last four bases complementary to the TAG-inserted
pattern, allowing for speciﬁc ampliﬁcation of the normal splicing pattern.
(C) Optimisation of the annealing and extension steps using the CLCN1 (5–7) pri-
mer set. Gradient PCR was performed in two steps using a denaturation step of
96 °C for 30 s, followed by a 30 s annealing and extension step using the pGEM-
TEasy plasmid vector containing the normal or TAG-inserted pattern as template.
The following temperatures for annealing and extension were used: 61.8 °C, 63.1 °C,
64.5 °C, 65.9 °C, 67.1 °C, 68.2 °C, 69.0 °C and 69.5 °C. Of these conditions, 67.1 °C was
chosen as the optimal temperature for speciﬁc ampliﬁcation of the normal splicing
pattern.
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Fig. 4. Results of the cellular splicing assay in HEK293 cells. (A) The expression of
each splicing factor was veriﬁed by Western blot. Splicing factor constructs (0.8 mg)
and the CLCN1 (5–7) minigene (0.2 mg) were co-transfected into HEK293 cells. Anti-
Myc antibody was used to detect each splicing factor containing a Myc tag; anti-
Actin was used as an internal control. (B) Expression of the CLCN1 normal splicing
pattern by real-time RT-PCR, relative to the expression of GFP in the CLCN1 (5–7)
minigene. MBNL1 induced a 4.5-fold increase in the expression of the normal
splicing pattern relative to controls; these effects were not seen with either MBNL2
or MBNL3. In contrast, CELF proteins tended to downregulate the expression of the
normal splicing pattern (n¼3). Bars indicate the mean and SEM; statistical sig-
niﬁcance was evaluated using Dunnett's multiple comparison test (**po0.05).
(C) The percentage of the TAG-inserted pattern in HEK293 cells co-transfected with
CLCN1 (5-7) minigene and MBNL1/pSec-DK (each n¼3). We performed RT-PCR and
sequenced the band corresponding to the normal splicing pattern 15–16 times for
each sample as the experiment of Fig. 2B. But, the percentage of TAG-inserted in-
clusion did not change upon MBNL1 overexpression.
T. Nakamura et al. / Biochemistry and Biophysics Reports 5 (2016) 63–69 67we therefore set the annealing and extension temperature for all
subsequent PCRs at 67 °C when using the CLCN1 (5–6–7) primer
set. Suitability of these conditions was validated by real-time PCR
(data not shown).
3.4. Quantiﬁcation of the normal splicing pattern of CLCN1
To investigate the effects of splicing factors MBNL1-3 and
CELF1-6, we performed a cellular splicing assay using the quan-
tiﬁcation method described above. Expression of each splicing
factor was conﬁrmed by Western blot (Fig. 4A). Expression of
MBNL1 signiﬁcantly increased the expression of 5–6–7 splicing
pattern transcripts 4.5-fold relative to controls; these effects were
not seen with either MBNL2 or MBNL3. These results are in stark
contrast to that of a previous report performed using Clcn1 [19],
highlighting the difference between human and mouse tran-
scripts. Moreover, CELF families tended to downregulate the ex-
pression of the 5–6–7 splicing pattern (Fig. 4B).
To conﬁrm whether MBNL1 regulates TAG-insertion splicing,
we performed normal RT-PCR and sequenced the band corre-
sponding to the normal splicing pattern 15–16 times for each cell
sample co-transfected with minigene and MBNL1/pSec-DK
(Fig. 4C). The ratio of TAG-inserted inclusion condition did not
change at all upon MBNL1 overexpression. MBNL1 increased not
only normal isoform but also TAG-inserted isoform. Therefore, we
conclude that MBNL1 does not regulate the TAG-insertion splicing,but promotes exon 6B and/or exon 7A skipping.
3.5. AONs induced exclusion of CLCN1 exons 6B and 7A
Next, we investigated whether AONs could induce 5–6–7 spli-
cing of CLCN1 using the quantiﬁcation method described above
(Fig. 5). Exon 7A (þ638) AON signiﬁcantly induced a 4-fold in-
crease in the expression of the 5–6–7 splicing pattern relative to
the control. Exon 7A (10þ15) AON also tends to increase the
expression of 5–6–7 splicing product. But other AONs did not
enhance 5–6–7 splicing. In the previous study, AON of exon 7a
(þ1þ25) on Clcn1 efﬁciently excluded exon 7a in vitro and in vivo
[23]. However, AON of exon 7a (þ1þ25) did not induce 5–6–7
splicing of CLCN1.4. Discussion
Here, we investigated human speciﬁc splicing of CLCN1, the
gene responsible for myotonia in DM, using an CLCN1 (5–7)
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Fig. 5. AON-mediated exclusion of CLCN1 exons 6B and 7A in HEK293 cells.
(A) Locations of the target sites of AONs (thick black lines) along the CLCN1 pre-
mRNA. (B) Results of the cellular splicing assay by AON in HEK293 cells. Expression
of the CLCN1 5–6–7 splicing product by real-time RT-PCR, relative to the expression
of all transcipts in the CLCN1 (5–7) minigene, was shown. Exon 7A (þ638) AON
was the most successful AON for inducing 5–6–7 splicing of CLCN1 minigene in
HEK293 cells (n¼3). Exon 7A (þ638) AON induced a 4-fold increase in the ex-
pression of the 5–6–7 splicing pattern relative to controls. Also, Exon 7A (10þ15)
AON tends to induce 5–6–7 splicing, whereas exon7A (þ1þ25) does not. Bars
indicate the mean and SEM; statistical signiﬁcance was evaluated using Dunnett's
multiple comparison test (**po0.01).
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vealed various splicing patterns, including the TAG-inserted pat-
tern, which encodes for a stop codon and is readily detected in
human skeletal muscle biopsies. To distinguish between these
various transcripts, we developed an RT-PCR assay speciﬁc for the
5–6–7 splicing pattern, regardless of the presence of other var-
iants. This assay was then used to quantify cellular splicing.
MBNL1 was shown to activate the expression of the 5–6–7 splicing
pattern, with no effects seen for either MBNL2 or MBNL3. This
result marks an important difference from that of our previous
reports using mouse Clcn1 [19]. In contrast to MBNL1, over-
expression of each CELF isoform decreased the expression of the
5–6–7 splicing pattern.
The TAG-inserted pattern is likely the cause of myotonia, as it
produces a stop codon just before exon 7 and can suppress the
expression of the 5–6–7 splicing pattern. Although we detected
the acceptor site responsible for this insertion, the overall function
of the TAG-inserted pattern remains unclear. In terms of its role in
DM, no signiﬁcant differences were observed in the percentage of
5–6–7 and TAG-inserted patterns between DM and controls.
However, as sequencing was performed only 15 times per in-
dividual, comparisons between these two groups may not be fully
reliable. We therefore needed to establish an assay that could be
used to speciﬁcally quantify the TAG-inserted pattern, as well as
investigate the TAG-inserted pattern in more detail. In this study,
we identiﬁed two tandemly repeated TAG sequences immediately
upstream of exon 7, one of which served as the splice acceptor site
for this exon. These two TAG sequences are conserved across a
range of species, including chimpanzees, dogs and mice, and have
been used in a variety of experiments investigating Clcn1 [10].
Hence, a more accurate assay method like the one described here
may be necessary for future examinations of Clcn1.
The assay system described here is able to directly quantify theproduction of 5–6–7 splicing pattern transcripts, an important
distinction as the expression of this protein is directly related to
the onset of myotonia. However, this assay was unable to quantify
other splicing variants. We will therefore need to establish addi-
tional assays such as direct RNA sequencing as a means of quan-
tifying the percentage of each splicing variant to better understand
the effects of splicing in CLCN1. Furthermore, this assay relied on
real-time PCR performed at relatively high annealing and exten-
sion temperatures to achieve transcript-speciﬁc ampliﬁcation of
the normal splicing pattern. As a result, variance in Ct-values be-
tween triplicates was detected. Further improvements will be
necessary to fully quantify the various splicing products produced
by this gene.
Using this new assay, we were able to detect differences in terms
of CLCN1 regulation between MBNL1 and MBNL2-3. All three MBNL
proteins bind CHG/CHHG sequences of RNA and have the same
amount of zinc ﬁnger domains, which are critical for recognising a
common consensus sequence in pre-mRNA and mRNA targets [22].
Splicing efﬁcacy therefore depends on differences in the target
genes themselves, as opposed to any speciﬁc MBNL protein. In fact,
our previous reports showed that the effects of each isoform dif-
fered based upon its target genes [13,14]. On the other hand, the
expression levels of MBNL2 and MBNL3 are weaker than that of
MBNL1 (Fig. 4A), which may have mediated the lower overall ef-
fects seen with these homologues. However, in our previous study
using Clcn1, we observed a similar tendency in terms of protein
expression; however, in this model, both MBNL2 and MBNL3 did
enhance the expression of the 5–6–7 splicing pattern [19]. More-
over, the effects of MBNL are regulated by a variety of other factors,
such as the secondary structure of mRNAs [22].
AON successfully alleviated the myotonic phenotype in DM
model mice [18,23]. To screen for an optimal AON sequence, we
used 25-mer phosphorothioate 2′ O-methyl RNA molecules that
covered the exon 6B or exon 7A. Unexpectedly, AON 7A (þ638)
which covers the boundary of intron 7A and exon 7A enhanced the
expression of 5–6–7 splicing product. Some AONs designed on
exon 7A excluded not only exon 7A but also exon 6B (Fig. 5).
Therefore we thought that the exclusion of exons 6B and 7A might
be related. AON of exon 7A (þ1þ25) which was the most suc-
cessful AON in mice did not enhance 5–6–7 splicing in human. We
therefore hypothesise that the differences seen between mice and
humans are the result of sequence differences between the human
and mouse orthologues of CLCN1, as sequence similarity in exons
5–7 is only 75% according to BLAST analysis.
In this study, we described differences in splicing patterns of
Clcn1 and CLCN1. These observations are important, as they sug-
gest that results obtained using Clcn1 do not necessarily apply to
CLCN1. Subsequent experiments should therefore focus on CLCN1,
as opposed to the mouse Clcn1 in investigations on CLCN1 for DM
medical treatments.Acknowledgements
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